A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetis and Pharmacodyhamics of VX-809 Alone and in Combination w/VX-770 in Subjects

Grants and Contracts Details

StatusFinished
Effective start/end date11/11/10 → 7/31/14

Funding

  • Vertex Pharmaceuticals Inc: $87,705.00